Markets

Insider Trading

Hedge Funds

Retirement

Opinion

These Stocks under $10 Are Poised To Explode

In this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode.

The US equity markets remain on track for a strong finish in 2023 as major indices hover near all-time highs. Easing inflation and a resilient economy that has avoided recession are factors that have catapulted the markets higher for the better part of the year. Will the rally continue into 2024? That’s the big question amid a wave of monetary and deteriorating macroeconomic uncertainties.

With the Federal Reserve indicating rate cuts in 2024, investors’ risk appetite is going to increase in the next year and small companies trading for low prices will come on investors’ radar. In this backdrop it would be interesting to see which under-$10 stocks have strong upside potential.

A close up shot of a stock ticker reflecting the performance of Indian equity markets.

Our Methodology

For this article we picked 10 stocks under $10 which have bullish ratings from analysts and price targets that show strong upside potential from their current levels. For each stock we have also mentioned hedge fund sentiment. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here). That’s why we pay very close attention to this often-ignored indicator.

These Stocks under $10 Are Poised To Explode

10. Annovis Bio, Inc. (NYSE:ANVS)

Share Price as of December 14: $9.70

Share Price Upside Potential: 230.39%

Number of Hedge Funds: 2

Annovis Bio, Inc. (NYSE:ANVS) is a cheap stock under $10 for anyone eyeing exposure in the healthcare sector. It operates as a clinical-stage drug platform that develops drugs for treating neurodegeneration conditions. Buntanetap, the lead product of Annovis Bio, Inc. (NYSE:ANVS), is in phase 3 trials for chronic neurodegenerative diseases like Alzheimer’s and Parkinson’s.

While Annovis Bio, Inc. (NYSE:ANVS) is down by 30% for the year, it has started showing signs of edging higher after bottoming out of all-time lows. The stock has exploded in recent weeks as its lead drug, Buntanetap, undergoes late-stage study in patients with Parkinson’s disease. Consensus estimates on Wall Street indicate Annovis Bio, Inc. (NYSE:ANVS) is a Strong Buy with a $30.33 price target, implying 230.39% upside potential.

Insider Monkey’s Q3 2023 survey of 910 hedge funds revealed that two had invested in Annovis Bio, Inc. (NYSE:ANVS).

9. ESSA Pharma Inc. (NASDAQ:EPIX)

Share Price as of December 14: $5.68

Share Price Upside Potential: 233.27%

Number of Hedge Funds: 12

ESSA Pharma Inc. (NASDAQ:EPIX) is a clinical-stage pharmaceutical company that focuses on the development of small-molecule drugs for the treatment of prostate cancer. ESSA Pharma Inc. (NASDAQ: EPIX)’s lead product is EPI-7386, an androgen receptor-based resistance mechanism that develops in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. 

After being consolidated for the better part of the year, ESSA Pharma Inc. (NASDAQ: EPIX) exploded in the second half and is up by about 114%. Analysts expect the rally to persist into 2024, going by the Buy rating and $18.33 price target, implying 233.27% upside potential.

ESSA Pharma Inc. (NASDAQ:EPIX) is getting the attention of smart money, as 12 elite hedge funds held stakes in the company in the third quarter of 2023.

8. electroCore, Inc. (NASDAQ:ECOR)

Share Price as of December 14: $5.50

Share Price Upside Potential: 236.54%

Number of Hedge Funds: 1

electroCore, Inc. (NASDAQ:ECOR) is another stock under $10 poised to explode, which is ideal for gaining exposure in the healthcare sector. electroCore, Inc. (NASDAQ:ECOR) operates as a commercial-stage bioelectronics medicine and wellness company. 

electroCore, Inc. (NASDAQ:ECOR) has gained about 35% year to date, outperforming the S&P 500, which is up by about 21%. Likewise, analysts on Wall Street are overly optimistic about electroCore, Inc. (NASDAQ:ECOR), with a Buy rating and a $17.50 price target, implying a 236.54% upside potential. One hedge fund was long electroCore, Inc. (NASDAQ:ECOR) in the third quarter of 2023.

7. Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

Share Price as of December 14: $1.31

Share Price Upside Potential: 237.41%

Number of Hedge Funds: 10

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) is another cheap stock under $10 poised to explode, operating as a clinical-stage pharmaceutical company that develops and commercializes therapies for people with rare genetic mitochondrial diseases. REN001, the lead product of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), is a strong and specific drug that activates a protein involved in energy metabolism. It is being tested for inherited diseases that affect the mitochondria.

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)’s been one of the best-performing cheap stocks in 2023, rallying by about 204%. Similarly, analysts on Wall Street expect the rally to persist into 2024, going by a $24.26 price target, implying a 237.41% upside potential.

By the end of this year’s September quarter, 10 out of the 910 hedge funds provided by Insider Monkey had acquired and held shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM).

6. Zepp Health Corporation (NYSE:ZEPP)  

Share Price as of December 14: $1.51

Share Price Upside Potential: 238.67%

Number of Hedge Funds: 3

Zepp Health Corporation (NYSE:ZEPP) is an innovative wearable and health technology company. The company empowers people to live lives by optimizing health, fitness, and wellness journeys through its consumer brands Amazfit, Zepp Clarity, and Zepp Aura. Zepp Health Corporation (NYSE:ZEPP) offers AI chips, biometric sensors, and data algorithms for its cloud-based actionable insights.

Zepp Health Corporation (NYSE:ZEPP) is up by about 3.4% for the year as analysts on Wall Street rate it as a buy with a $5.08 price target, implying a 238.67% upside potential. Zepp Health Corporation (NYSE:ZEPP) trades at highly discounted levels, going by the 5.13 price-to-earnings ratio.

According to Insider Monkey’s third-quarter database, three hedge funds were bullish on Zepp Health Corporation (NYSE:ZEPP), the same as the previous quarter.

Click to continue reading and see The 5 Stocks Under $10 That Are Poised To Explode.

Suggested articles:

Disclosure: None. These Stocks under $10 Are Poised To Explode is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

  • The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
  • Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
  • Lifetime Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

  1. Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
  2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
  3. Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…